There are 3164 resources available
959P - Machine learning-based MRI radiomics predicts overall survival of unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus PD-(L)1 inhibitors and molecular targeted therapy
Presenter: Bin-Yan Zhong
Session: Poster session 17
960P - Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening
Presenter: Hee-Jung Wang
Session: Poster session 17
961P - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve oncologic outcomes in diabetic patients with hepatocellular carcinoma (HCC): A nationwide database study
Presenter: Chien-Huai Chuang
Session: Poster session 17
962P - Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effort
Presenter: Pablo Azcue
Session: Poster session 17
963P - Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab + rivoceranib (cam+rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Presenter: Andrew Moon
Session: Poster session 17
964P - Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)
Presenter: Markus Peck Radosavljevic
Session: Poster session 17
967P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster session 17
968P - HAIC combined with lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors for advanced HCC with portal vein tumor thrombosis: A prospective controlled trial
Presenter: Xiaodong Wang
Session: Poster session 17
969P - Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
Presenter: Pasquale Lombardi
Session: Poster session 17